The company said the divestiture of its medical imaging business in the fourth quarter reduced revenues to below previous guidance.
The bank rated companies like Thermo Fisher Scientific and Agilent at Buy, Illumina and PerkinElmer at Hold, and Myriad Genetics and Luminex at Sell.
The investment bank set a price target of $18.00 for shares of the molecular diagnostics company.
The investment bank provided the updates as part of its 2017 outlook on the US life science tools and diagnostics markets.
Evercore said that Hologic's recent divestiture of its blood screening business limits near-term EPS growth; Piper, however, is looking forward to 2018.
The bank said that although it is forecasting a 17 percent stronger flu season this year, Quidel's influenza sales are only likely to rise 10 percent.
The investment bank also changed ratings for several omics companies, and revised price targets and estimates throughout its portfolio.
The investment bank noted Veracyte's "disciplined" approach to developing and commercializing tests, and said the company stands out in its sector.
The investment bank said Veracyte's negative classifier tests are of significant value to healthcare providers and payors.
The investment bank said Danaher's recent acquisitions of Cepheid and Phenomenex increase its potential for revenue growth.
In PNAS this week: diatom genetic diversity, microfluidic droplet method for single-cell screening, and more.
Scientific publishers are looking into whether artificial intelligence can help the peer-review process, Wired reports.
Researchers are using gene editing to develop more robust livestock and crops, AFP reports.
Researchers rally near the American Association for the Advancement of Science annual meeting in Boston.